RxDoctor Payments Data

Sweeya Ramireddy, MD

Internal Medicine · Houston, TXNPI 1366644767

Payments from drug & device makers

$5,708in general payments, 2019–2025

Across 319 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$933
  • Lilly USA, LLC$675
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$366
  • Merck$319
  • AstraZeneca$305
  • Boehringer Ingelheim$238
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$5,708100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,708 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$122,718
Medicare patients
265
Services billed
2,462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$70,469
MounjaroTirzepatide38$51,543
FarxigaDapagliflozin Propanediol38$42,411
EliquisApixaban25$33,730
ProliaDenosumab16$26,174
JardianceEmpagliflozin15$25,186
MyrbetriqMirabegron14$18,718
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$14,854
Breo ElliptaFluticasone/Vilanterol17$10,507
ShingrixVaricella-Zoster Ge/As01b/Pf35$7,646
SynthroidLevothyroxine Sodium75$6,158
SymbicortBudesonide/Formoterol Fumarate11$4,942
Atorvastatin Calcium339$4,335
Levothyroxine Sodium307$2,741
Sertraline Hcl126$2,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$933$70,46944 claims
Lilly USA, LLCMounjaro$675$51,54338 claims
AstraZenecaFarxiga, Symbicort$305$47,35349 claims
PfizerEliquis$159$33,73025 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$185$33,00771 claims
AmgenProlia$69$26,17416 claims
Boehringer IngelheimJardiance$238$25,18615 claims
Astellas Pharma US IncMyrbetriq$126$18,71814 claims
AbbVieSynthroid$234$6,15875 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →